A Phase 3, Multicenter, Randomized, Open Label Study Of Ifinatamab Deruxtecan (I Dxd), A B7-H3 Antibody Drug Conjugate (Adc), Versus Treatment Of Physician’s Choice (Tpc) In Subjects With Relapsed Small Cell Lung Cancer (Sclc). This app is specifically intended for participants in the ds7300-188 study only.
Show More
